This review highlights biomarkers for disease activity and treatment response in ANCA-associated vasculitis, suggesting improved management strategies.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare autoimmune diseases with multisystemic organ involvement. Their pathogenesis remains incompletely understood, and reliable biomarkers for disease activity and treatment response are lacking. This review explores current and emerging biomarkers in AAVs to identify disease phenotypes and activity, aiming to optimize management and immunosuppressive treatment. Serological, cellular, and urinary biomarkers will be discussed, focusing on their current utility in clinical practice for assessing disease activity, damage related to the disease, and prognosis. Promising biomarkers and novel methodologies for detecting future biomarkers will also be briefly discussed.
No takes yet. Share an insight, caveat, or question.
Marvisi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Frontiers in Immunology